Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marina Biotech and ProNAi Therapeutics have entered into an exclusive licensing contract for SMARTICLES liposomal delivery technology.
Subscribe to our email newsletter
The liposomal delivery technology is used in the development and commercialization of DNAi-based therapeutics.
As per the agreement, Marina could receive up to $14m for each gene target in total upfront, clinical and commercialization milestone payments, royalties on sales.
ProNAi will be responsible for the development and commercialization of any products arising under the agreement and has the option to select any number of additional gene targets.
The companies have not disclosed further terms of the agreement.
ProNAi president and CEO Charles Bisgaier said the delivery technology offers protection for the DNAi oligonucleotide during systemic administration with good circulation times and extrahepatic tumor exposure.
Marina president and CEO Michael French said the company has entered into a relationship with ProNAi that is developing a first-in-class nucleic acid therapeutic.